Kallistem obtains complete human spermatozoa in vitro

07-May-2015 - France

Kallistem, which develops cell culture technologies in reproductive biology, announces a world first: human spermatogenesis in vitro. At the end of 2014 the company was able to produce fully formed human spermatozoa in the laboratory setting, using patient testicular biopsies containing only immature germ cells, or spermatogonia.
 
A number of teams throughout the world have been trying for over 15 years to achieve human spermatogenesis in vitro. Spermatogenesis is an extremely complex physiological process that takes 72 days in vivo. To achieve this world first, Kallistem is leveraging two innovative, patented technologies capable of meeting current regulatory standards.
 
The company is setting up a therapeutic development project for patients whose fertility is at risk. Preclinical trials are expected to last until 2016, with clinical trials starting in 2017. Kallistem’s five-year objective is to market its technologies under license to suppliers in the assisted reproductive technology market, as well as selling them directly to public and private fertility clinics.
 

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper
View topic world
Topic world Cell culture technology

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper